Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | IARS1 | P41252 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.49 |
| ▸ | TUBB | P07437 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002022 | 0.88 | ALDH1A1 (0.67) | GAATSHRNFKB1CYP1A2CYP3A4 | |
| SCHEMBL30038050 | 0.88 | ALDH1A1 (0.67) | GAATSHRNFKB1CYP1A2CYP3A4 | |
| SCHEMBL908271 | 0.87 | ABL1 (0.59) | GAACYP1A2CYP3A4SMN1; SMN2EPHX2 | |
| SCHEMBL12191688 | 0.86 | L3MBTL1 (0.50) | GAATSHRNFKB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1011093 | 0.85 | GAA (0.73) | GAATSHRNFKB1CYP1A2CYP3A4 | |
| SCHEMBL491225 | 0.85 | CYP19A1 (0.60) | GAATSHRNFKB1CYP1A2CYP3A4 | |
| SCHEMBL8733776 | 0.85 | GAA (0.63) | GAATSHRNFKB1CYP1A2CYP3A4 | |
| SCHEMBL4140693 | 0.83 | YWHAG (0.68) | GAATSHRNFKB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL31741653 | 0.83 | YWHAG (0.68) | GAATSHRNFKB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3782064 | 0.83 | LMNA (0.55) | GAATSHRCYP1A2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| CN-109890822-B | Inhibitors of cellular metabolic processes | 安吉奥斯医药品有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2019-08-01 | — | — | US | disclosed |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2019-08-01 | — | — | US | disclosed |
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3507290-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | Agios Pharmaceuticals, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-1121363-B1 | 6-SUBSTITUTED PYRAZOLO(3,4-d)PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1383769-A2 | 6-SUBSTITUTED PYRAZOLO 3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
| US-6559152-B2 | For therapy of cancer or other proliferative diseases | DUPONT PHARMACEUTICALS COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-6531477-B1 | Treating cancer or other proliferative diseases | DUPONT PHARMACEUTICALS COMPANY | 2003-03-11 | — | — | US | disclosed |
| WO-2002067654-A3 | 6-SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002067654-A2 | 6-SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-09-06 | — | — | WO | disclosed |
| US-20020013328-A1 | 6-Substituted pyrazolo[3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| EP-1121363-A2 | 6-SUBSTITUTED PYRAZOLO 3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021926-A2 | 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013328-A1 | 6-Substituted pyrazolo[3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors | CCNK, CCNI, CDK1 | GAA 2616/4885TSHR 3380/4885NFKB1 369/4885 |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | GAA 968/4885TSHR 2620/4885NFKB1 3090/4885 |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | GAA 968/4885TSHR 2620/4885NFKB1 3090/4885 |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | GAA 968/4885TSHR 2620/4885NFKB1 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.